Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes
批准号:
9986280
负责人:
XIAOYING WANG
金额:
$25.12万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-02 至 2021-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Diabetic stroke patients have higher mortality and worse neurological outcomes. Emerging clinical and
experimental data suggest that BBB disruption, neuroinflammation, and stroke recovery impairment are
exacerbated in T2D. Hence, the goal of this project is to investigate therapeutic approaches that can target
these specific T2D mechanisms in stroke. Fibroblast Growth Factor-21 (FGF21) is a circulating endocrine
hormone that is primarily expressed in the liver. FGF21 has pleiotropic metabolic actions, but also has tissue
protective and repair roles. Here, we will test the overall hypothesis that exogenous recombinant human
FGF21 (rFGF21) activates FGFR1--klotho complex that may ameliorate T2D-affected mechanisms after
stroke via: (1) activation of PPAR for BBB protection, (2) inhibition of NFB-mediated but activation of PPAR
for neuroinflammation modulation, (3) promotion of AMPK/Nrf2-mediated vascular/white matter remodeling to
boost neurorestoration after stroke.
Aim 1. Investigate rFGF21 effects on blood-brain barrier integrity in T2D stroke mice. We will examine FGF21
specific receptor FGFR1 phosphorylation, PPAR activity, BBB integrity, hemorrhagic transformation,
expression of vascular inflammatory molecules and tight junction proteins, are assessed up to 3 days after
stroke (dMCAO) in db/db T2D mice, and T2D stroke in vitro model of brain endothelial/astrocytes co-cultures.
Aim 2. Investigate rFGF21 effects on neuroinflammation in T2D stroke. We will examine NFB and PPAR
activation, and correlation with microglia/macrophage activation, pro-inflammatory factor expression in peri-
lesion area by RT-PCR, immunohistochemistry, western blots, and flow cytometry after focal dMCAO stroke in
T2D mice, and in primary microglia cultures in vitro. Aim 3. Investigate rFGF21 effects on vascular/white
matter remodeling in T2D stroke. We will examine activation of AMPK and Nrf2, expression of trophic factors in
isolated brain microvascular fragments and brain tissues by western blot analysis, immunohistochemistry, and
mRNA microarray. We will also test biomarkers of vascular and white matter remodeling over time by
immunohistochemistry, RT-PCR and western blots after ischemic stroke of T2D mice, and in vitro models of
primary human brain endothelial cultures and oligodendrocyte cultures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Irg-1/itaconate in modulating secondary brain damage after traumatic brain injury in mice
-
批准号:10594260
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2023
-
负责人:XIAOYING WANG
-
依托单位:
Annexin A2 as a cerebrovascular therapy in traumatic brain injury
-
批准号:9986277
-
项目类别:
-
资助金额:$12.92万
-
财政年份:2019
-
负责人:XIAOYING WANG
-
依托单位:
Annexin A2 as a cerebrovascular therapy in traumatic brain injury
-
批准号:9231513
-
项目类别:
-
资助金额:$37.54万
-
财政年份:2015
-
负责人:XIAOYING WANG
-
依托单位:
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy
-
批准号:8193720
-
项目类别:
-
资助金额:$85.04万
-
财政年份:2011
-
负责人:XIAOYING WANG
-
依托单位:
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy
-
批准号:8317528
-
项目类别:
-
资助金额:$139.92万
-
财政年份:2011
-
负责人:XIAOYING WANG
-
依托单位:
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy
-
批准号:8541066
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:XIAOYING WANG
-
依托单位:
Recombinant annexin A2 plus tPA for combination stroke therapy
-
批准号:8103811
-
项目类别:
-
资助金额:$37.28万
-
财政年份:2010
-
负责人:XIAOYING WANG
-
依托单位:
Recombinant annexin A2 plus tPA for combination stroke therapy
-
批准号:7986573
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2010
-
负责人:XIAOYING WANG
-
依托单位:
Recombinant annexin A2 plus tPA for combination stroke therapy
-
批准号:8495432
-
项目类别:
-
资助金额:$35.98万
-
财政年份:2010
-
负责人:XIAOYING WANG
-
依托单位:
Recombinant annexin A2 plus tPA for combination stroke therapy
-
批准号:8287076
-
项目类别:
-
资助金额:$37.28万
-
财政年份:2010
-
负责人:XIAOYING WANG
-
依托单位:
Recombinant annexin A2 plus tPA for combination stroke therapy
-
批准号:8697146
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2010
-
负责人:XIAOYING WANG
-
依托单位:
Neuroprotective Mechanisms of Neuroglobin in Stroke
-
批准号:7030382
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2006
-
负责人:XIAOYING WANG
-
依托单位:
Neuroprotective Mechanisms of Neuroglobin in Stroke
-
批准号:7342901
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2006
-
负责人:XIAOYING WANG
-
依托单位:
Neuroprotective Mechanisms of Neuroglobin in Stroke
-
批准号:7544451
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2006
-
负责人:XIAOYING WANG
-
依托单位:
Neuroprotective Mechanisms of Neuroglobin in Stroke
-
批准号:7159366
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2006
-
负责人:XIAOYING WANG
-
依托单位:
Neuroprotective Mechanisms of Neuroglobin in Stroke
-
批准号:7748926
-
项目类别:
-
资助金额:$33.42万
-
财政年份:2006
-
负责人:XIAOYING WANG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于FGF21/FGFR1轴探究鼠尾草酸甲酯改善肝细胞胰岛素抵抗的作用机制
-
批准号:2026JJ80987
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:江军仪
-
依托单位:
FGF21通过CTL1介导的胆碱稳态调控线粒体自噬对帕金森病的保护机制研究
-
批准号:MS25H310003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李晨
-
依托单位:
FGF21/NRF2/PSMB5调控线粒体稳态在儿童川崎病免疫性冠状动脉损伤中的作用机制
-
批准号:2025JJ80990
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王运初
-
依托单位:
心梗后心肌释放的细胞外囊泡通过上调
肝脏FGF21促进损伤心肌修复
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:韩超珊
-
依托单位:
自驱动纳米“发电机”系统递送FGF21时空调控LRP1重塑线粒体转运治疗脊髓损伤机制研究
-
批准号:ZYQ25H300001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:左彦明
-
依托单位:
有氧运动通过FGF21/AMPK信号轴调控脂噬改善小鼠骨骼肌胰岛素抵抗机制研究
-
批准号:2025JJ50647
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:刘元
-
依托单位:
FGF21通过激活Sirt1-自噬信号轴减轻急性胰腺炎的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:殷俊杰
-
依托单位:
FGF21通过缓解氧化应激改善糖尿病伴发抑郁症状和神经血管单元损害的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王琼章
-
依托单位:
限时进食对米色脂肪生成的促进作用及FGF21介导的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
FGF21/GLP1 双靶融合蛋白治疗2 型糖尿病的协同降糖
作用及机制
-
批准号:2024JJ3039
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:肖扬
-
依托单位: